Safety of gadoxetate disodium: Results from the clinical phase II–III development program and postmarketing surveillance

Publisher： John Wiley & Sons Inc

E-ISSN： 1522-2586|42|3|634-643

ISSN： 1053-1807

Source： JOURNAL OF MAGNETIC RESONANCE IMAGING, Vol.42, Iss.3, 2015-09, pp. : 634-643

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 118-125

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II/III trial of a pre‐transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 4, 2015-04 ,pp. : 629-636

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of intraoral ranulas with micromarsupialization: Clinical outcomes and safety from a phase II clinical trial

By  

HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol. 37, Iss. 2, 2015-02 ,pp. : 197-201

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 620-628

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite